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Background: Patients with claudication secondary to peripheral artery disease have a substantial impairment in walking
capacity. This study evaluated factors suspected to be correlated with treadmill walking performance in an effort to gain
insights into the pathophysiology of the impairment.
Methods: A multivariate model was developed to deﬁne the associations between clinical and laboratory biomarkers with
treadmill peak walking time (PWT) in patients enrolled in three clinical trials. The model was initially developed in
a cohort of 385 patients from one trial using 23 candidate-independent variables and then tested in the combined data
from the other two trials (351 patients).
Results: The ﬁnal model was built from 14 variables that met the predeﬁned univariate criteria of P < .15. Main effects
remaining in the model were age, resting ankle-brachial index, smoking status, hypertension, statin use, country (United
States vs non-United States countries), and high-sensitivity C-reactive protein. The model was highly statistically
signiﬁcant (P < .0001) but explained only a limited portion of the population heterogeneity (r2 [ 0.173). The main
effects plus interaction terms had an r2 [ 0.2178. The main effects model was tested in an independent cohort of 351
patients from two other clinical trials in peripheral arterial disease that did not include high-sensitivity C-reactive protein.
The model successfully ﬁt the data set, based on prospectively deﬁned root mean squared error and was statistically
signiﬁcant (P [ .0005) but had lower overall explanatory power than in the index cohort (r2 [ 0.0687).
Conclusions: As expected, age and ankle-brachial index contributed to exercise limitation among patients with PAD. The
association of C-reactive protein, hypertension, and smoking with PWT is consistent with a role for inﬂammation or
oxidative stress in determining treadmill walking performance. In contrast to previous reports from smaller and more
homogenous populations, clinical attributes and biomarkers explain only a small portion of PWT heterogeneity. (J Vasc
Surg 2013;58:396-403.)Atherosclerosis in the lower extremities associated with
peripheral artery disease (PAD) results in impairment of
blood ﬂow. Patients with PAD have impaired physical
performance in ambulatory and laboratory settings.1,2
Claudication, the classic symptom of exertional pain in
patients with PAD, is often the factor limiting exercisethe Harbor-University of California Los Angeles (UCLA) Center for
linical Pharmacology, Torrancea; the Division of Cardiology, Mayo
linic, Rochesterb; and CPC Clinical Research,c and the Division of
ardiology, University of Colorado School of Medicine,d Aurora.
or conﬂict of interest: E.P.B. was a compensated consultant for Kowa
esearch Institute Inc, and Sigma tau Pharmaceuticals, sponsors of two of
e studies used in this article, and serves as a consultant to other compa-
es with business interests in the area of peripheral arterial disease. L.T.C.
ceived consulting income from Kowa Research Institute Inc. P.H. is
ployed by CPC Clinical Research, a nonproﬁt research center afﬁliated
ith the University of Colorado. W.R.H. received consulting income for
ials in peripheral artery disease structured as a contract between
e sponsor and CPC Clinical Research, from Aastrom, AstraZeneca,
NAVEC, Kowa Research Institute Inc, Pluristem, Sigma tau Pharma-
uticals, Takeda, and Theravasc.
rint requests: Leslie T. Cooper Jr, MD, Director, Gonda Vascular
enter, Mayo Clinic, 200 First St SW, Rochester, MN 55906 (e-mail:
oper.leslie@mayo.edu).
editors and reviewers of this article have no relevant ﬁnancial relationships
disclose per the JVS policy that requires reviewers to decline review of any
anuscript for which they may have a conﬂict of interest.
-5214/$36.00
yright  2013 by the Society for Vascular Surgery.
://dx.doi.org/10.1016/j.jvs.2012.12.077tolerance for these patients, but PAD patients without
typical claudication are also signiﬁcantly impaired.3 The
degree of blood-ﬂow limitation can be estimated using
the ankle-brachial index (ABI), which compares blood
pressures in the arms and the affected lower extremity.
Although ABI is correlated with physical performance in
cohorts that include healthy individuals and PAD patients,
it is a relatively weak predictor of the degree of impairment
in an ambulatory, diverse PAD population.2,4,5 These
observations suggest that factors in addition to large vessel
blood ﬂow contribute to the exercise limitation. Changes
in muscle metabolism, maldistribution of blood ﬂow,
muscle and endothelial injury due to inﬂammatory media-
tors, and altered nerve function are just some of the mech-
anisms proposed that might contribute to the functional
status of these patients.6-8
Several investigators have looked at clinical character-
istics and blood biomarkers in an effort to better under-
stand the heterogeneity in physical performance and
outcomes in patients with PAD.4,5,9-13 These studies
often have not had sufﬁciently large cohorts or compre-
hensive data to allow simultaneous evaluation of multiple
potential factors of interest. Recent clinical trials designed
to assess pharmacotherapies intended to improve exercise
performance in patients with claudication have generated
large databases with comprehensive clinical evaluations
and robust functional assessments. These large data sets
Table I. A, Values for the proposed dichotomous
independent variables in the two patient populations
Variables
Index cohort
(n ¼ 387),
No. (%)
Testing cohort
(n ¼ 351),
No. (%)
Sex
Male 334 (86.3) 273 (77.8)
Female 53 (13.7) 78 (22.2)
Race
White 370 (95.6) 316 (90.0)
Other 17 (4.4) 35 (10.0)
Smoking status
Current 204 (52.7) 128 (36.5)
Never or past history 183 (47.3) 223 (63.5)
Country
United States 96 (24.8) 183 (52.1)
Russia 291 (75.2) 126 (35.0)
Brazil 0 42 (12.0)
Diabetes 60 (15.5) 93 (26.5)
Hypertension 282 (72.9) 294 (83.8)
Hypercholesterolemia 332 (85.8) 306 (87.2)
Statin use 164 (42.4) 131 (37.3)
ACE inhibitor 121 (31.3) 105 (29.9)
Creatinine >2 mg/dL 2 (0.5) 5 (1.4)
ACE, Angiotensin-converting enzyme.
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ations between clinical biomarkers and physical perfor-
mance in a diverse cohort of patients with claudication.
The current study used baseline data from a large trial
to generate a model correlating multiple clinical and
biomarker variables with treadmill peak walking time
(PWT) in an effort to gain insights into the pathophysi-
ology of the physical impairment. The model was then
tested in an independent data set from two additional clin-
ical trials.
METHODS
Patients. A cohort of 385 patients with complete data
enrolled in a previously published study of the phosphodi-
esterase inhibitor K-134 served as the index cohort for the
current analyses.14 Data from 351 patients enrolled in two
additional trials comprised the testing data set.15,16 Details
on patient cohorts are provided in the original publications.
On entry, cilostazol, pentoxifylline, or carnitine was not
allowed in the study from which the index cohort was
derived or in one of the two studies contributing to the
testing data set.14,15 However, cilostazol was allowed in the
second study contributing to the testing cohort, which
affected 36 individuals.16
These threemultisite studies enrolled patients with clau-
dication secondary to PAD. Comprehensive clinical assess-
ments, including determination of treadmill PWT, were
performed on entry. PWT in all studies was assessed on
a graded treadmill using an established protocol.17 All
participants received familiarization with the treadmill
before formal assessments. PWT was deﬁned as the time in
seconds between the start of the treadmill and the point at
which participants could walk no further. In all cases, exer-
cise was limited by claudication symptoms. All ABI assess-
ments were made at rest using standard methodologies.18
Similar inclusion and exclusion criteria were used in the
three trials, and assessment methodologies were consistent
across the trials. For purposes of the current analyses,
a patient’s PWT was deﬁned as the highest PWT obtained
from either of the ﬁrst two baseline studies performed.
Hypertension was deﬁned by a medical history, the use
of antihypertensive medications, or measured systolic
blood pressure >140 mm Hg and diastolic blood pressure
>90 mm Hg. Hypercholesterolemia was deﬁned by
a medical history, a total cholesterol >200 mg/dL or
low-density lipoprotein >100 mg/dL, or treatment with
a lipid-lowering drug.
Model development. Twenty-three candidate-inde-
pendent variables were identiﬁed based on previous work
done in PAD patients (Table I, A). Variables were
treated as dichotomous or continuous, with all deﬁnitions
and cutoffs prespeciﬁed before any analyses. Total bilirubin
was originally included as a dichotomous variable with
a demarcation at two times the upper limit of normal, but
no patients exceeded this limit and was thus not included in
further analyses.19
Each independent variable was tested for association
with treadmill PWT in the index cohort. Owing to thenon-normal distribution of PWTs in the tested cohort,
and consistent with the original protocols, PWT underwent
logarithmic transformation, expressed as the natural loga-
rithm of the PWT in seconds (ln(PWT)). A two-sample
t-test was used to assess the difference between the group
means for dichotomous variables. For continuous variables,
linear regression was used to generate slope coefﬁcients for
each variable, along with P and r values. P values were
calculated to allow screening of candidate-independent
variables for inclusion in the ﬁnal model, with a threshold
of <.15 required. The statistical analyses used SAS 9.2
software (SAS Institute Inc, Cary, NC).
Backward elimination was used to build the multivar-
iate analysis of covariance model, which initially included
all independent variables with univariate association
P value <.15. The analysis-of-covariance model was then
run, with P values generated for each variable. Any variable
that subsequently had a P >.15 was eliminated from the
model. This iterative process was continued until all
remaining variables had P values <.15. Any individual
missing data for an independent variable retained in the
model was excluded from the ﬁnal analysis, resulting in
385 evaluable participants in the index cohort. Two-way
interactions between the remaining variables were subse-
quently included in a forward-selection manner. All inter-
action terms that yielded P < .15 were incorporated into
the ﬁnal primary model that was characterized by the coef-
ﬁcient for each term, the overall P value, the r2, and the
root mean square error (RMSE).
Testing of the model. The multivariate model devel-
oped was used to evaluate the testing cohort. If the ﬁnal
model included an independent variable not available in
the testing data set, the coefﬁcient for that variable was
Table I. B, Values for the proposed continuous
independent variables in the two patient populations
Variables
Index cohorta Testing cohorta
Mean 6 SD Mean 6 SD
Peak walking time,
seconds
282 6 155 318 6 169
Age, years 63.5 6 8.6 65.7 6 8.5
Body mass index,
kg/m2
26.6 6 4.4 27.6 6 4.8
Systolic blood pressure,
mm Hg
132.2 6 13.9 137.3 6 13.3
Ankle-brachial index 0.62 6 0.15 0.64 6 0.16
Hemoglobin, g/dL 14.7 6 1.4 14.5 6 1.5
Albumin, g/dL 4.4 6 0.3 4.2 6 0.4
White blood cell count,
109/L
7.8 6 2.3 7.7 6 2.1
Glucose, mg/dL 106 6 29 112 6 38
Uric acid, mg/dL 6.1 6 1.4 ND
hsCRP, mg/L 6.67 6 9.58 (n ¼ 358) ND
Fibrinogen, g/L 4.01 6 1.04 (n ¼ 375) ND
Interleukin-6, pg/mL 4.69 6 6.23 (n ¼ 386) ND
D-dimer, ng/mL 371 6 452 (n ¼ 299) ND
hsCRP, High-sensitivity C-reactive protein; ND, not determined; SD,
standard deviation.
an ¼ 387 for index cohort and n ¼ 351 for the testing cohort except where
indicated.
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procedure. The model was considered valid if the RMSE
for the testing cohort was no greater than 125% of the
index cohort (excluding any variables not in both data
sets).
RESULTS
Development of the model. The clinical characteris-
tics of the index cohort used for model development
were representative of a population with claudication
except for the over-representation of patients in Russia
and the associated under-representation of nonwhite
patients and women (Table I, A and B). Among the
dichotomous variables, race, smoking status, diabetes,
hypertension, statin use, use of blood pressure medications,
and country of origin all had a P < .15 threshold for
association with treadmill performance (Table II, A).
Among continuous variables, age, BMI, ABI, white blood
cell count, high-sensitivity C-reactive protein (hsCRP),
ﬁbrinogen, and interleukin (IL)-6 yielded linear regressions
with P < .15 (Table II, B). Representative scatterplots for
ABI and hsCRP are shown in Figs 1 and 2.
A multivariate model was developed as described
above. The main effects model (Table III) included age,
ABI, smoking status, hypertension, statin use, country,
and hsCRP. The main effects model had a P < .001, an
r2 ¼ 0.1727, and a RMSE ¼ 0.53401 log-seconds. There
were signiﬁcant interactions between age and smoking, age
and statin use, smoking and statin use, hypertension and
ABI, and ABI and country; for example, the quantitative
association between age and PWT was inﬂuenced by
smoking status. This model with the main effects and inter-
actions had a P < .0001, an r2 ¼ 0.2178, and a RMSE ¼
0.52275 log-seconds. Without hsCRP, the r2 ¼ 0.1861.
Because the effect of the interaction terms on the RMSE
was minimal and much less than the 25% criterion prospec-
tively established for testing, the interaction terms have
been omitted for clarity from the presented model
(Tables III and IV).
From the model, a reference patient was developed
using the mean values for each ﬁxed-effect variable
(Table IV) to allow better visualization of the quantitative
contributions of each main effect variable on PWT (linear
scale). Thus, the reference patient could be constructed
as being 64 years old, with an ABI of 0.62, and a CRP
of 6.67 mg/L. Dichotomous variables were ﬁxed for this
reference standard as current smoker, hypertensive, a non-
user of statins, and not from the United States. With this
baseline, for a 10-year increase in age, there is a 17.2-
second loss in mean PWT; for a 0.10 increase in ABI, there
is a 12.9-second increase in mean PWT; and for CRP,
a 1.0-mg/L increase is associated with a 2.4-second
decrease in mean PWT. Statin use was associated with
a 29.5-second loss in PWT. Current smoking, hyperten-
sion, and Russian origin were all associated with lower
PWT values than the respective comparison. For example,
smoking decreased PWT by 21.2 seconds in the context of
the reference patient. Thus, although all terms contributedto the ﬁnal model in a statistically signiﬁcant way, their
quantitative association varied considerably.
Model testing. The model was applied to a separate
cohort of 351 patients, of whom 347 had data for all vari-
ables other than hsCRP. Because none of the participants
had hsCRP due to the study protocols, this term was set
to 0 and therefore did not contribute to the model. The
demographics of this cohort were very similar to that of
the index cohort, except only 36% were from Russia
(52% from United States and 12% from Brazil). The
application of the main effects model was statically signif-
icant (P ¼ .0005) and yielded an r2 ¼ 0.0687 and
RMSE ¼ 0.54038 log-seconds. Removal of the 36
participants taking cilostazol slightly changed the r2 to
0.0684. Thus, the criterion for a successful test was met
(RMSE in the testing cohort <125% of the RMSE in the
index cohort).
DISCUSSION
Insights into the pathophysiology of the walking
impairment in patients with PAD have been hampered by
a lack of access to a large population with diverse clinical
characteristics, including patients enrolled from multiple
sites and multiple countries. From an analysis of a large,
well-characterized patient cohort, a multivariate model
was created that identiﬁed biomarkers associated with
functional status. This model was tested in another large,
independent patient cohort. The model conﬁrms the ex-
pected associations of age and ABI with functional status,
and the ﬁndings are consistent with contributions of
inﬂammatory markers and inducers of oxidative stress.
Perhaps the most surprising ﬁnding is that although highly
Table II. B, Association of continuous variables with
peak walking time in the index cohort (n ¼ 385)a
Independent variablea Slopeb P
Age per year 0.00656 .101
Body mass index 0.0159/(kg/m2) .040
Systolic blood pressure 0.00068/mm Hg .778
Ankle-brachial index 1.019 <.001
Hemoglobin 0.0171/(g/dL) .464
Albumin 0.0146/(g/dL) .901
White blood cell count 0.0217/(109 cells/L) .148
Uric acid 0.00113/(mg/dL) .965
Glucose 0.00025/(mg/dL) .837
HsCRP 0.0112/(mg/L) .001
Fibrinogen 0.0807/(g/L) .017
Interleukin-6 0.0122/(pg/mL) .019
D-dimer 0.00006/(ng/mL) .452
hsCRP, High-sensitivity C-reactive protein.
aLinear regression was used to determine the association between the
independent variable and peak walking time expressed as ln(PWT in
log-seconds).
bSlopes represent the change in ln(PWT) per unit change in the indepen-
dent variable.
Table II. A, Association of dichotomous variables with
peak walking time (PWT) in the index cohort (n ¼ 385)a
Dichotomous variable lnPWT P
Arithmetic
Mean 6 SD
Sex
Male 5.49 .67 283 6 155
Female 5.45 275 6 158
Race
White 5.47 .016 277 6 151
Nonwhite 5.81 394 6 199
Smoking status
Current 5.42 .023 261 6 144
Former or never 5.55 305 6 164
Diabetes
Yes 5.62 .047 319 6 158
No 5.46 275 6 154
Hypertension
Yes 5.45 .08 274 6 152
No 5.57 302 6 162
Hypercholesterolemia
Yes 5.48 .719 283 6 159
No 5.5 275 6 133
Statin
Yes 5.4 .021 263 6 151
No 5.54 295 6 157
ACE inhibitor
Yes 5.4 .063 264 6 157
No 5.52 290 6 154
Country
United States 5.71 <.001 342 6 161
Russia 5.41 262 6 148
Creatinine >2 mg/dL
Yes 5.61 .748 332 6 265
No 5.48 282 6 155
ACE, Angiotensin-converting enzyme; SD, standard deviation.
aPWT in seconds is reported for each dichotomous group for each candidate
variable as ln(PWT in seconds). Decisions for model development and
the P values (two-sample t-test) were based on log-transformed PWT.
Arithmetic mean values are also presented.
Fig 1. Scatter plot of ankle-brachial index (ABI) vs peak walking
time (PWT) in linear seconds in the index cohort. The equation is
ABI vs PWT ¼ 226.2  (ABI þ 141.5).
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 2 Brass et al 399statistically signiﬁcant, the r2 of only 0.2178 for the model
containing main effects with hsCRP and interaction terms
in the index cohort says that w80% of the heterogeneity
in PWT remains unexplained.
Arterial obstruction by atherosclerotic lesions is the
primary pathophysiologic event in claudication due to
PAD. However, consistent with earlier studies, ABI was
only weakly associated with the degree of functional
impairment (Table II, B and Fig 1).4,5 This suggests
that oxygen delivery to the exercising muscle is not the
major limiting factor for function in chronic PAD. Consis-
tent with this, blood hemoglobin concentration, which
with blood ﬂow is the major determinant of oxygen
delivery, was not associated with treadmill performance
(Table II, B). Hemoglobin in the test development data
set ranged from 9.2 to 17.8 g/dL, which might have facil-
itated a correlation had one been present. However, the
standard deviation of the hemoglobin distribution was
small, potentially masking a relationship between hemo-
globin and PWT. Upper extremity systolic blood pressure,which estimates the driving pressure for ﬂow through the
obstruction, was not associated with PWT. More impor-
tant, ABI is likely a poor surrogate for blood ﬂow during
exercise, and more sophisticated assessments in small
patient cohorts have suggested a stronger relationship
between blood ﬂow and exercise performance than would
be suggested by ABI.20 Nonetheless, these observations
and hypotheses suggest that changes to vascular regulation
and muscle metabolism or function distal to the ﬂow
obstruction contribute to the functional disability in these
patients.
Fig 2. Scatter plot of C-reactive protein (CRP) vs peak walking
time (PWT) in linear seconds in the index cohort. The equation is
CRP vs PWT ¼ 2.97  (CRP þ 301.8).
Table III. Model developed using the index cohort
(n ¼ 385)a
Independent variable/interaction term Model coefﬁcient
Age (in) 0.00830/y
Ankle-brachial index (in) 0.580/1.0 change
Smoking status (out)
Never/former 0
Current 0.0939
Hypertension (in)
No 0
Yes 0.1339
Statin (out)
No 0
Yes 0.1470
Country (in)
Non-United States 0
United States 0.3387
hsCRP (in) and log hemoglobin 0.0111/(mg/L)
hsCRP, High-sensitivity C-reactive protein.
aOnly main effects are included (see text). Independent variables and
interaction terms in the model are listed with ln(peak walking time [PWT]
in log-seconds) as the dependent variable. The intercept is ln(PWT) of 5.85.
The model has a P < .0001 and an r2 ¼ 0.1727.
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smoking status, diabetes, white blood cell count, hsCRP,
ﬁbrinogen, and IL-6, all factors associated with inﬂamma-
tion or oxidative stress, appeared associated with treadmill
performance (Tables II and III). Nylaende et al21 previ-
ously reported an association between IL-6 and treadmill
performance in patients with PAD. Inﬂammatory and
oxidative stress biomarkers have been associated with
PAD in other studies, and direct evidence of oxidativeinjury in muscle has also been reported.22-25 In the ﬁnal
model, only hsCRP was included (Table III), suggesting
that these various biomarkers were reﬂecting similar patho-
physiology that was best represented by the serum hsCRP
concentration. Similar relationships have been found in
other disease cohorts.26 Atherosclerosis itself is recognized
to be an inﬂammatory condition associated with oxidative
stress.27 Thus, the association of hsCRP with PWT may
simply reﬂect the atherosclerotic burden or activity or
may be a surrogate for an ongoing pathophysiology that
results in functionally important changes in limb vascula-
ture or skeletal muscle.
An important role for oxidative stress may help to
explain the association between hypertension and PWT,
despite the lack of association with measured blood pres-
sure or antihypertensive drugs (Tables II and III), because
hypertension is also associated with increased oxidative
stress.27,28 Increased levels of inﬂammatory biomarkers
are also associated with decreased ambulatory physical
activity in patients with PAD.10 The strength of smoking
status in the ﬁnal model, accounting for almost 21 seconds
of PWT, also supports the potential importance of oxida-
tive injury in walking impairment. Smoking status was
a strong quantitative component of the ﬁnal model
(Table IV). This suggests a role of smoking independent
of the chronic sequelae of tobacco abuse. Smoking is asso-
ciated with an acute increase in free radical stress,29,30
which in turn may affect endothelial and vascular function
through decreased nitric oxide30 and contribute to muscle
injury.25 The model also supports the rationale for advising
patients to stop smoking to improve functional status and
long-term morbidity and mortality.31
The differential functional status in participants from
Russia is not understood. Because country effect remained in
the ﬁnal model, none of the measured variables appear to ex-
plain this effect. In addition, participants from Russia appear
to respond differentially to some pharmacotherapies.14,32
The current study failed to conﬁrm some functional
associations observed in patients with PAD by others using
different assessment methods, including hypercholesterol-
emia and D-dimer concentration.9,13 Whether these reﬂect
cohort or methodologic differences is unclear. Similarly,
statin treatment has been reported to improve performance
in patients with claudication and be associated with less
decrease in function over time, but statin use in this study
was associated with a modestly lower PWT in the current
analyses.33,34 Although the reasons for these discrepant
results are not known, statins are associated with muscle
adverse events that may affect performance.35
The age and, often, life-style histories of PAD patients
place them at risk for signiﬁcant comorbidities, including
arthritis, lung disease, and congestive heart failure. The
contribution of these comorbidities to functional status in
patients with PAD has been established in epidemiologic
studies.36,37 More important, the clinical trials from which
the current data set were derived used exclusion criteria for
conditions that would affect treadmill performance,
including arthritis, chronic obstructive pulmonary disease,
Table IV. The associations between the main effects variables and peak walking time (PWT) from the full modela
Independent variable Effect on mean PWT
Age 17.2-second decrease for a 10-year increase in age
ABI 12.9-second increase for a 0.10 increase in ABI
Smoking status 21.2 seconds less for current smoker vs never/former
Hypertension 30.9 seconds less for hypertension vs no hypertension
Statin 29.5 seconds for statin use
Country 87.0 seconds more for USA vs Russia
hsCRP 2.37-second decrease for a 1 mg/L increase in hsCRP
ABI, Ankle-brachial index; hsCRP, high-sensitivity C-reactive protein.
aThe reference patient was considered a 64-year-old individual with an ABI of 0.62, a current smoker, hypertensive, not a statin user, not from the USA, and
with an hsCRP of 6.67 mg/L. The mean ln(PWT) of this typical patient was 5.37 log-seconds. This is equivalent to 216 seconds on a linear scale.
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heart failure. These exclusions precluded the assessment of
the role of these diseases in the model developed, and some
contribution of unrecognized disease cannot be eliminated.
However, the exclusion also increased the likelihood that
associations identiﬁed were attributable to the PAD-
induced limitation.
Despite the relatively complete list of clinical attributes
and biomarkers included in the analysis, only a relatively
small fraction of the heterogeneity in functional status
in the population could be explained. This is consistent
with a complex pathophysiology for exercise impairment
for which blood ﬂow limitation and atherosclerosis are
proximal initiators but incompletely describe the integra-
tive result. For example, skeletal muscle metabolic status
has been hypothesized to contribute to physical impair-
ment and would not be captured by the biomarkers
studied.7,38,39 In small studies, biomarkers of skeletal
muscle metabolism have been correlated with treadmill
performance.40,41
The patient cohorts used in the analyses had relative
under-representation of women and nonwhites. Previous
work has suggested potential sex-based and race-based
differences in the clinical course, epidemiology, and mani-
festations of PAD.42,43 The current analyses may have been
underpowered to assess the interaction of sex and race with
the main factors identiﬁed as associated with walking
performance.
Although providing important insights into the PAD
population, the approach used has several limitations.
The index cohort was selected based on the availability of
data on a wide range of parameters of interest. In contrast,
data for the testing cohort were more limited. Thus, the
application of the model to the testing cohort cannot be
viewed as rigorous validation but is illustrative of consis-
tency of the model based on the prospectively deﬁned
criteria. The patient populations studied met speciﬁc
criteria for purposes of the clinical trials and thus excluded
segments of the general PAD population. For example,
patients without claudication were excluded, as were
patients unable to complete treadmill testing. Women
and ethnic minorities were under-represented in the
cohorts. It is also not clear how the effect of exercise
training would affect these associations.Not all potential biomarkers were studied, and given
the residual unexplained population heterogeneity, meta-
bolic, neurologic, and other factors may signiﬁcantly
contribute to functional status. In some cases, the distri-
bution of the continuous variables was limited (eg,
albumin ranged only from 3.3 to 5.2 mg/dL in the index
cohort) or the distribution of dichotomous variables
skewed (eg, only two patients in the index cohort had
creatinine >2 mg/dL), limiting their potential contribu-
tion to the model developed.
The index cohort included a large number of patients
from Russia, and country of origin was a signiﬁcant
contributor to the ﬁnal model. It is possible that the model
incompletely adjusts for this country effect, and thus, the
general applicability might be limited. Unassessed demo-
graphic or clinical parameters may contribute to the
country effect. However, the testing cohort included
a smaller contribution of patients from Russia, and the
model remained statistically signiﬁcant. Patients in the
index and testing cohorts were different in some clinical
characteristics (Table I). However, the successful evalua-
tion of the model in the testing cohort supports the utility
of the parameters identiﬁed.
CONCLUSIONS
The model developed reinforces the heterogeneity in
functional status in patients with PAD and the complex
pathophysiology that contributes to functional impairment.
Factors other than acute oxygen delivery to muscle during
exercise likely contribute to this impairment and may repre-
sent novel targets for intervention in an effort to improve
physical performance in these patients.
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